Context

MedinCell is a clinical-stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients that are already known and marketed.

BEPO® technology makes it possible to control the delivery of a drug at the optimal therapeutic level through subcutaneous or local injection of a fully bioresorbable deposit.

MedinCell has strong partnerships with Teva (schizophrenia), AiC (pain), and the Bill & Melinda Gates Foundation (contraception).

Its most advanced schizophrenia product, with Teva, went through phase 3 in November 2020.
• This capital raise follows positive phase 3 results announced with Teva in January 2021.

The proceeds will be used to finance formulation/R&D activities, and preclinical/clinical studies in the following therapeutic areas: organ transplantation, pain treatment and preventive treatment against Covid-19 (Ivermectin). They will also be used to accelerate the development of MedinCell’s technological platform for other applications, for example, animal health, pulmonary and cardiovascular diseases.

Medincell_website_tombstone

About MedinCell

MedinCell is a clinical-stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Discover MedinCell

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }

Privacy Preference Center